Drug Trial Radar · NCT03320070
Acthar Gel in Participants With Pulmonary Sarcoidosis
Last checked: Nov 20, 2026Latest source record: Feb 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
55
Actual
Start
Feb 21, 2018
Primary completion
Nov 15, 2021
Study completion Nov 15, 2021
Sponsor
- Lead sponsor
- MallinckrodtIndustry
- Sponsor type
- Industry
- First posted
- Oct 25, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to find out if Acthar Gel is safe and effective to treat pulmonary sarcoidosis. Participants will be randomly assigned (like flipping a coin) to receive a shot under their skin of Acthar Gel or a matching placebo gel that has no drug in it. They will receive their assigned shot twice a week for 24 weeks. All participants who complete the 24-week treatment period will be eligible to receive Acthar Gel for 24 more weeks, even if they were originally in the placebo group.
Conditions
- Sarcoidosis, Pulmonary
Interventions
Acthar GelDrug
Acthar Gel for subcutaneous (SC) injection (80 units per 1 mL)
PlaceboDrug
Placebo gel for SC injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- DBT: Number of Participants in Each Category of Assessment Based on Forced Vital Capacity (FVC), a Pulmonary Function Test Parameter at Week 24Time frame: Week 24
- OLE: Number of Participants in Each Category of Assessment Based on FVC, a Pulmonary Function Test Parameter at Week 48Time frame: Week 48
- DBT: Number of Participants in Each Category of Assessment Based on the Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO), a Pulmonary Function Test Parameter at Week 24Time frame: Week 24
- OLE: Number of Participants in Each Category of Assessment Based on the DLCO, a Pulmonary Function Test Parameter at Week 48Time frame: Week 48
- DBT: Number of Participants in Each Category of Assessment Based on High Resolution Computer Tomography (HRCT) at Week 24Time frame: Week 24
- OLE: Number of Participants in Each Category of Assessment Based on HRCT at Week 48Time frame: Week 48
- DBT: Number of Participants in Each Category of Assessment Based on the King's Sarcoidosis Questionnaire (KSQ) (General Health), a Quality of Life Parameter at Week 24Time frame: Week 24
- OLE: Number of Participants in Each Category of Assessment Based on the KSQ (General Health), a Quality of Life Parameter at Week 48Time frame: Week 48
- DBT: Number of Participants in Each Category of Assessment Based on the Fatigue Assessment Score (FAS), a Quality of Life Parameter at Week 24Time frame: Week 24
- OLE: Number of Participants in Each Category of Assessment Based on FAS, a Quality of Life Parameter at Week 48Time frame: Week 48
- DBT: Number of Participants in Each Category of Assessment Based on Corticosteroid Taper Score in Participants Receiving Each Dose of Prednisone at Week 24Time frame: Week 24
- OLE: Number of Participants in Each Category of Assessment Based on Corticosteroid Taper Score in Participants Receiving Each Dose of Prednisone at Week 48Time frame: Week 48
Locations
29 sites in 1 country. Site status is shown where the registry gives one.
UAB Lung Health Center
Birmingham, Alabama
David Geffen School of Medicine
Los Angeles, California
National Jewish Health
Denver, Colorado
University of Florida Division of Pulmonary, Critical Care, and Sleep Medicine
Gainesville, Florida
University of Miami Miller School of Medicine
Miami, Florida
Central Florida Pulmonary Group PA
Orlando, Florida
Rush University Medical Center
Chicago, Illinois
Laporte County Institute For Clinical Research
Michigan City, Indiana
University of Kansas Medical Center
Kansas City, Kansas
Howard County Center for Lung and Sleep Medicine, LLC
Columbia, Maryland
Washington University School of Medicine
St Louis, Missouri
Valley Medical Group
Ridgewood, New Jersey
Albany Medical Center
Albany, New York
American Health Research Inc
Charlotte, North Carolina
Duke University Medical Center
Durham, North Carolina
Clinical Research of Gastonia
Gastonia, North Carolina
University of Cincinnati Medical Center
Cincinnati, Ohio
Cleveland Clinic
Cleveland, Ohio
Penn State Milton S Hershey Medical Center
Hershey, Pennsylvania
Temple Lung Center
Philadelphia, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Berks Schuylkill Respiratory Specialists, Ltd
Wyomissing, Pennsylvania
VitaLink Research - Anderson
Anderson, South Carolina
Medical University of South Carolina - PPDS
Charleston, South Carolina
Clinical Research of Charleston
Mt. Pleasant, South Carolina
Clinical Research of Rock Hill
Rock Hill, South Carolina
VitaLink Research - Spartanburg
Spartanburg, South Carolina
University of Texas Southwestern Medical Center
Dallas, Texas
University of Texas Health Science Center at Tyler
Tyler, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.